A recent Reuters article noted that the FDA has taken away the emergency use authorization of bebtelovimab, Eli Lilly’s COVID-19 monoclonal antibody treatment. The agency said the drug is not expected to neutralize the dominant subvariants of Omicron. The decision narrows the treatment options to four: Pfizer’s Paxlovid and Merck’s Lagevrio, Gilead’s Veklury, and AstraZeneca’s Evusheld. Commercial distribution of bebteloviman bas been halted until further notice from the agency.
FDA Retracts Approval of Eli Lilly’s COVID Drug
The agency doesn’t think Bebtelovimab adequately neutralizes the dominant BQ.1 and BQ1.1 subvariants of Omicron.
Dec 7, 2022